Gangliosides -- A new therapeutic agent against stroke and Alzheimer's disease

doi:10.1016/0024-3205(94)00393-9

Life Sciences

Volume 55, Issues 25–26, 1994, Pages 2125-2134

https://doi.org/10.1016/0024-3205(94)00393-9 Get rights and content

Abstract

Gangliosides are glycosphingolipids localized to the outer leaflet of the plasma membrane of vertebrate cells. The highest ganglioside concentration of any organ is found in the mammalian brain, where the gangliosides are enriched in the neuronal membrane, particularly in the synapses. There are four major brain gangliosides with the same neutral tetrasaccharide core to which one to three sialic acids are linked - the simplest being the GM1-ganglioside. These gangliosides have been shown to have neuritogenic and neuronotrophic activity and to facilitate repair of neuronal tissue after mechanical, biochemical or toxic injuries. Mixtures of native bovine brain gangliosides were adopted for pharmacological use in the treatment of peripheral nerve damage, and GM1-ganglioside has been applied for the treatment of CNS injuries and diseases. Beneficial effects of GM1 have been documented in the treatment of stroke and spinal cord injuries, particularly when the treatment has been initiated within a few hours of the acute event. Continuous intraventricular infusion of GM1 has recently been shown to have a significant beneficial effect in Alzheimer disease of early onset (AD Type I).

References (81)

L. Svennerholm et al.
Biochim Biophys Acta
(1989)
F.J. Sharom et al.
Biochim. Biophys Acta
(1978)
S.D. Skaper et al.
Dev. Brain Res.
(1985)
J.R. Sparrow et al.
Exper. Neurol.
(1982)
M. Kalia et al.
Neurosci. Lett.
(1982)
A. Gorio et al.
Neuroscience
(1983)
M. Wojcik et al.
Neuroscience
(1982)
S.E. Karpiak
Exp. Neurol.
(1983)
A.C. Cuello et al.
Brain Res.
(1986)
P.L. Dipatre et al.
Brain Res.
(1989)

G. Ferrari et al.

Dev. Brain Res.

(1983)

L. Svennerholm

Novel therapeutic strategies for dementia diseases

H. Iber et al.

Eur. J. Biochem.

(1991)

D.S. Forman et al.

Science

(1972)

C.-A. Landa et al.

J. Neurochem.

(1979)

C.-G. Gottries et al.

Neurochem Int.

(1991)

H.A. Hansson et al.

H. McIlwain

Biochem J.

(1961)

H. McIlwain

L. Svennerholm

J. Neurochem.

(1964)

K. Suzuki

J. Neurochem.

(1967)

M.T. Vanier et al.

J. Neurochem.

(1971)

A. Dreyfus et al.

Neurosci.

(1980)

A.J. Yates

Neurochem Pathol.

(1986)

H. Rösner et al.

Gangliosides and Modulation of Neuronal Functions

J. Holmgren et al.

Infect. Immun.

(1973)

J. Holmgren et al.

J. Moss et al.

G. Toffano et al.

Neurochem.

(1980)

S. Kanda et al.

J. Biochem.

(1982)

R.W. Ledeen

J. Neurosci. Res.

(1984)

S.P. Mahadik et al.

Drug. Dev. Res.

(1988)

A. Consolazione et al.

F.J. Roisen et al.

Science

(1981)

W. Dimpfel et al.

A. Leon et al.

Develop. Neurosci.

(1982)

M.C. Byrne et al.

J. Neurochem.

(1983)

R. Katoh-Semba et al.

J. Neurosci. Res.

(1984)

A. Leon et al.

J. Neurosci. Res.

(1984)

O. Doherty et al.

J. Neurochem.

(1985)

Cited by (94)

Varieties, production, composition and health benefits of vinegars: A review
2017, Food Chemistry
Citation Excerpt :
ASL have a significant effect in improving cognitive ability, as they contain highly pure free dihydroceramide, a precursor to various sphingolipids such as gangliosides (Fukami et al., 2010), which are composed of sialic acid- and ceramide-conjugated oligosaccharides (Svennerholm, 1994). These sialic acid- and ceramide-conjugated oligosaccharides have been shown to be effective in improving the symptoms of Alzheimer patients (Svennerholm, 1994). Additionally, cider vinegar has been reported to have the ability to balance pH levels in the body if taken regularly (Brown & Jaffe, 2000).
Vinegars are liquid products produced from the alcoholic and subsequent acetous fermentation of carbohydrate sources. They have been used as remedies in many cultures and have been reported to provide beneficial health effects when consumed regularly. Such benefits are due to various types of polyphenols, micronutrients and other bioactive compounds found in vinegars that contribute to their pharmacological effects, among them, antimicrobial, antidiabetic, antioxidative, antiobesity and antihypertensive effects. There are many types of vinegars worldwide, including black vinegar, rice vinegar, balsamic vinegar and white wine vinegar. All these vinegars are produced using different raw materials, yeast strains and fermentation procedures, thus giving them their own unique tastes and flavours. The main volatile compound in vinegar is acetic acid, which gives vinegar its strong, sour aroma and flavour. Other volatile compounds present in vinegars are mainly alcohols, acids, esters, aldehydes and ketones. The diversity of vinegars allows extensive applications in food.
Multi-target-directed therapeutic potential of 7-methoxytacrine-adamantylamine heterodimers in the Alzheimer's disease treatment
2017, Biochimica et Biophysica Acta - Molecular Basis of Disease
Citation Excerpt :
The prevention of Aβ peptide aggregation is therapeutically attractive since amyloid aggregation is exclusively pathological process and therefore, targeted inhibition of Aβ fibrillization should not interfere with the physiological function of the amyloid precursor protein as well as other proteins participating in Aβ peptide production [12,13]. Different classes of compounds were identified as inhibitors of amyloid aggregation including a variety of small molecules [13–18], polyamines [19,20], metal chelators [21], osmolytes [22], carbohydrate-containing compounds [23,24], short peptides [25,26] or polyphenols [27,28]. Although the amyloid hypothesis represents the main stream nowadays, the cholinergic hypothesis provides another approach which refers to substantial neocortical deficits in the enzyme choline acetyltransferase (ChAT, E.C. 2.3.1.6) responsible for the synthesis of acetylcholine (ACh) [29–31].
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and currently there is no efficient treatment. The classic drug-design strategy based on the “one-molecule-one-target” paradigm was found to be ineffective in the case of multifactorial diseases like AD. A novel multi-target-directed ligand strategy based on the assumption that a single compound consisting of two or more distinct pharmacophores is able to hit multiple targets has been proposed as promising. Herein, we investigated 7-methoxytacrine - memantine heterodimers developed with respect to the multi-target-directed ligand theory. The spectroscopic, microscopic and cell culture methods were used for systematic investigation of the interference of the heterodimers with β-secretase (BACE1) activity, Aβ peptide amyloid fibrillization (amyloid theory) and interaction with M1 subtype of muscarinic (mAChRs), nicotinic (nAChRs) acetylcholine receptors (cholinergic theory) and N-methyl-d-aspartate receptors (NMDA) (glutamatergic theory). The drug-like properties of selected compounds have been evaluated from the point of view of blood-brain barrier penetration and cell proliferation. We have confirmed the multipotent effect of novel series of compounds. They inhibited effectively Aβ peptide amyloid fibrillization and affected the BACE1 activity. Moreover, they have AChE inhibitory potency but they could not potentiate cholinergic transmission via direct interaction with cholinergic receptors. All compounds were reported to act as an antagonist of both M1 muscarinic and muscle-type nicotinic receptors. We have found that 7-methoxytacrine - memantine heterodimers are able to hit multiple targets associated with Alzheimer's disease and thus, have a potential clinical impact for slowing or blocking the neurodegenerative process related to this disease.
Identification and functional characterization of intracellular sialidase NeuA3 from Streptomyces avermitilis
2015, Process Biochemistry
Citation Excerpt :
It is involved in nervous system development and function, and modulates the functions of various membrane proteins [15,34,35]. There have been many recent clinical applications of GM1 for treatment of human neurological and other disorders, including Alzheimer's disease, Parkinson's disease, spinal cord injury, and stroke [5–9,36]. GM1 is usually extracted and purified from mammalian (particularly bovine) brain.
Sialidases (EC 3.2.1.18), glycosidases that cleave the linkages whereby sialic acids are attached to glycoconjugates, are found in most bacterial species. Because sialidases can convert polysialogangliosides to monosialoganglioside GM1, they have potential clinical application for treatment of human neurological and other disorders including Alzheimer's disease, Parkinson's disease, and spinal cord injury. Sialidases with high substrate specificity are desirable for more efficient GM1 production. In this study, the sialidase neuA3 gene from the non-pathogenic bacterium Streptomyces avermitilis, which is commonly used for industrial applications, was analyzed, cloned, and expressed in E. coli BL21 (DE3). Purified NeuA3 enzyme was characterized using 2′-(4-methylumbelliferyl)-α-d-N-acetylneuraminic acid (4-MUN) as a synthetic substrate. NeuA3 has a low molecular weight (∼38 kDa), showed strong stability in the presence of various divalent metal ions and temperature and pH values, preferentially cleaved α2,3- and α2,6-linked sialic acids from gangliosides, and efficiently converted crude porcine brain gangliosides to GM1. NeuA3 treatment of malignant human bladder cancer cells YTS-1 presented enhanced cell surface expression of GM1. The novel sialidase NeuA3 will be useful for functional studies of sialylated oligosaccharides and other sialoglycoconjugates, especially for studying the functions of GM1 in cancer research.
The influences of sphingolipid metabolites on gentamicin-induced hair cell loss of the rat cochlea
2010, Neuroscience Letters
Sphingolipid metabolites inducing ceramide, sphingosine, and sphingosine-1-phosphate (S1P) play important roles in the regulation of cell proliferation, survival, and death. Aminoglycoside antibiotics including gentamicin induce inner ear hair cell loss and sensorineural hearing loss. Apoptotic cell death is considered to play a key role in this injury. The present study was designed to investigate the possible involvement of ceramide and S1P in hair cell death due to gentamicin. In addition, the effects of other metabolites of ceramide, gangliosides GM1 (GM1) and GM3 (GM3), on gentamicin ototoxicity were also investigated. Basal turn organ of Corti explants from p3 to p5 rats were maintained in tissue culture and exposed to 20 or 35 μM gentamicin for 48 h. The effects of ceramide, S1P, GM1, and GM3 on gentamicin-induced hair cell loss were examined. Gentamicin-induced hair cell loss was increased by ceramide but was decreased by S1P. GM1 and GM3 exhibited protective effects against gentamicin-induced hair cell death at the limited concentrations. These results indicate that ceramide enhances gentamicin ototoxicity by promoting apoptotic hair cell death, and that S1P, GM1, and GM3 act as cochlear protectants. In conclusion, sphingolipid metabolites influence the apoptotic reaction of hair cells to gentamicin ototoxicity.
Modulation of amyloid precursor protein processing by synthetic ceramide analogues
2010, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Previous studies suggest that membrane lipids may regulate proteolytic processing of the amyloid precursor protein (APP) to generate amyloid-beta peptide (Abeta). In the present study, we have assessed the capacity for a series of structurally related synthetic ceramide analogues to modulate APP processing in vitro. The compounds tested are established glucosylceramide synthase (GS) inhibitors based on the d-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) structure. PDMP and related compounds PPMP and EtDO-P4 inhibited Abeta secretion from Chinese hamster ovary cells expressing human APP (CHO-APP) with approximate IC₅₀ values of 15, 5, and 1 μM, respectively. A trend for reduced secretion of the APP alpha-secretase product, sAPPalpha, was also observed in PDMP-treated cells but not in PPMP- or ETDO-P4-treated cells, whereas levels of the cellular beta-secretase product APP C-terminal fragment, CTFbeta, were increased by both PDMP and PPMP but unaltered with EtDO-P4 treatment. Our data also revealed that EtDO-P4 inhibits endogenous Abeta production by human neurons. In conclusion, this study provides novel information regarding the regulation of APP processing by synthetic ceramide analogues and reveals that the most potent of these compounds is EtDO-P4.
Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis
2010, Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids
Sphingolipids in the membranes of neurons play important roles in signal transduction, either by modulating the localization and activation of membrane-associated receptors or by acting as precursors of bioactive lipid mediators. Activation of cytokine and neurotrophic factor receptors coupled to sphingomyelinases results in the generation of ceramides and gangliosides, which in turn, modify the structural and functional plasticity of neurons. In aging and neurodegenerative conditions such as Alzheimer's disease (AD), there are increased membrane-associated oxidative stress and excessive production and accumulation of ceramides. Studies of brain tissue samples from human subjects, and of experimental models of the diseases, suggest that perturbed sphingomyelin metabolism is a pivotal event in the dysfunction and degeneration of neurons that occurs in AD and HIV dementia. Dietary and pharmacological interventions that target sphingolipid metabolism should be pursued for the prevention and treatment of neurodegenerative disorders.

View all citing articles on Scopus

View full text

Gangliosides -- A new therapeutic agent against stroke and Alzheimer's disease

Abstract

Biochim Biophys Acta

Biochim. Biophys Acta

Dev. Brain Res.

Exper. Neurol.

Neurosci. Lett.

Neuroscience

Neuroscience

Exp. Neurol.

Brain Res.

Brain Res.

Dev. Brain Res.

Eur. J. Biochem.

Science

J. Neurochem.

Neurochem Int.

Biochem J.

J. Neurochem.

J. Neurochem.

J. Neurochem.

Neurosci.

Neurochem Pathol.

Gangliosides and Modulation of Neuronal Functions

Infect. Immun.

Neurochem.

J. Biochem.

J. Neurosci. Res.

Drug. Dev. Res.

Science

Develop. Neurosci.

J. Neurochem.

J. Neurosci. Res.

J. Neurosci. Res.

J. Neurochem.